opicapone (ONGENTYS)

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

treatment of off episodes in Parkinson's disease patients treated with levodopa/carbidopa

Dosage

once daily

Tabs: 25 mg, 50 mg

Adverse effects

Mechanism of action

selective catechol-O-methyltransferase inhibitor (COMT inhibitor)

More general terms

References

↑ CISION PR Newswire. April 27, 2020 Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes. https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-once-daily-ongentys-opicapone-as-an-add-on-treatment-for-patients-with-parkinsons-disease-experiencing-off-episodes-301047469.html

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=135565903

Retrieved from "https://aaushi.info/w/index.php?title=A56191&oldid=916715"

↑ Back to top